Download our full report on India Globalization Capital HERE
Marijuana is the fastest growing industry in the world and the industry is just getting started.
From Canada to Australia and Mexico to Germany, the legal marijuana industry continues to grow and is already a multi-billion-dollar market.
Marijuana is becoming big business and the industry’s rapid growth has led to the creation of new high-growth sub-industries. Although there are numerous opportunities around the sale of legal cannabis, we believe the greatest and most profitable opportunities can be found on the biotech and healthcare side of the industry.
Biotech Beneficiaries of the Marijuana Movement
The biotech sector will be one of the greatest beneficiaries of the legal cannabis movement and we have already identified several leaders focused on this opportunity.
Marijuana is medicine. Biotech firms focused on developing treatments that are derived from marijuana have been successful. GW Pharmaceuticals’ Sativex product is derived from cannabis and treats patients with Multiple Sclerosis. Currently, Sativex is being sold in 27 countries.
Biotech stocks do not trade like your normal investment. While companies like Apple (APPL) and Ford (F) tend to trade on earnings and revenue, biotech companies trade on FDA data and approvals.
A Biotech Firm to Watch
Last week, NYSE-traded India Globalization Capital, Inc. (IGC) announced its fiscal year 2017 financial results. The company is developing a product portfolio of phytocannabinoid-based therapies through cutting edge research for the treatment of a wide range of therapeutic indications.
Focused on Indications with Large Addressable Markets
IGC is focused on developing treatments for indications including neuropathic and cancer pain, epilepsy, end of life supportive care, adjunctive supportive therapies of chronic neurological and oncological diagnosis, which are life altering or life threatening.
Much of IGC’s value is derived from its intellectual property and previously filed patents. In 2014, the company filed a patent for IGC-501 and IGC is currently finalizing the product development by conducting anecdotal testing. Later that year, IGC filed a patent for IGC-504
In February 2017, IGC filed a patent for IGC-506 which is used to treat eating disorders. The company expects to file an additional patent to finalize these products later this year while advancing its refractory epilepsy treatment for dogs and cats (IGC-505 and IGC-503).
credit:420intel.com